Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA regarding their EPA medication (Vascepa) for the lowering of triglycerides. I believe the difficulty #AMRN has had with the FDA in the past has made the market concerned about Vascepa's future given recent announcement of an advisory committee meeting for label expansion of Vascepa. I also talk about Sarepta, Novartis and Gilead. This is not investment advice. Please do your own due diligence before ever investing in equity markets. www.breakingbiotech.com http://epadruginitiative.com/press/why-the-fda-got-it-wrong Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech